The results for human review you are referring to in that study are those that the APAS could not reliably segregate as 'no growth' or 'significant growth' on first pass, they are 'review' results that need someone to view the image before the next step in the automation chain .. ALL positive results ie. 'Significant growth' and 'review' must be confirmed by an alternative method, be that a scientist or molecular/biochemical method.. As the author states 'with the groupings designed as a guide for interpretation and not as a replacement for formal identification procedures.' No positive final laboratory reports will be issued based on the APAS result alone.
So as you say (and i've carried on about previously) it's all about the negatives, the APAS is currently the only system doing that with full confidence. BUT
Both BD and Copan are not far off this capability, their systems already spot negatives cultures easily and BD at least have a software upgrade to their existing systems that will give their labs APAS's ability to report negatives at that step in the automation chain.
They've trademarked the BD Optis name, so are obviously somewhat serious about releasing it. It may not even require FDA approval given that the system itself is already approved and this is merely a software upgrade. Submit a few validation studies and Optis may be good to go!
BD and Copan systems are already in the market, changing lab workflows and building reputations. Some software/sensor upgrades to these systems may decimate the LBT/CCS advantage.
Look I think it's just something to consider, of course either manufacturer may take a shortcut and partner with LBT/CCS. Then again they might not. I just think as an investor you need to properly understand the market your company is entering into and it's hurdles. It's foolish to just believe what the company present to you in a newsletter or powerpoint slide.
Would be nice if this thread could be about the science and application of LBTs tech.. The fanboys are welcome to ignore it discuss CRs, IOLs and fibonacci retraces elsewhere.
xx
LBT Price at posting:
46.5¢ Sentiment: Buy Disclosure: Not Held
(20min delay)